Comparison of Frozen Embryo Transfer Outcomes Between Uterine Infusion of Granulocyte Colony-Stimulating Factor and Growth Hormone Application in Patients With Thin Endometrium: A Retrospective Study.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of endometriosis, published as a clinical trial.

To investigate the effect of two treatments on the outcome of freeze-thaw embryo transfer for pregnancy assistance in thin endometrium.

Who Took Part

The abstract describes 66 patients taking part.

The age groups tagged for this paper are adults, women only.

A retrospective study was conducted on 66 patients who failed in the first cycle treated in the reproductive medicine center of the Second Hospital of Hebei Medical University from January 2018 to December 2019.

The clinical data of the two groups were compared, including morphology and thickness of the endometrium, biochemical pregnancy rate, clinical pregnancy rate, implantation rate, miscarriage rate, and live birth rate in each period of the hormone replacement cycle.

What Was Measured

PubMed files the paper under topics including Cryopreservation, Embryo Implantation, Embryo Transfer, Endometrium, Granulocyte Colony-Stimulating Factor, Growth Hormone and Pregnancy Rate.

The authors tagged it with the keywords colony cell stimulating factor, frozen-thaw embryo transfer, pregnancy outcome and thin endometrium.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 66 patients in people with endometriosis.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Endometriosis research.